NCT00362570View on ClinicalTrials.gov

Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

March 31, 2011

Conditions
Oligoastrocytoma, MixedAnaplastic Oligodendroglioma
Interventions
DRUG

Temozolomide

"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00362570 - Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | Biotech Hunter | Biotech Hunter